EUVIMEDEUVIMED entdecken
Open Access

Generation of recombinant viruses directly from clinical specimens of COVID-19 patients

Hirotaka Yamamoto iD, Tomokazu Tamura iD, Takaya Ichikawa, Yudai Taguchi, Kento Mori, Satoshi Oguri, Rigel Suzuki, Saori Suzuki, Takanori Teshima iD, Takasuke Fukuhara iD

Journal of Clinical Microbiology · 2024

DOI: 10.1128/jcm.00042-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Microbiology, 2024. Verfasst von Hirotaka Yamamoto und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Japan. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19, Saliva, RNA, Viral. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Japan Agency for Medical Research and Development (AMED), MEXT | Japan Society for the Promotion of Science (JSPS), MEXT | Japan Science and Technology Agency (JST).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Rapid characterization of the causative agent(s) during a disease outbreak can aid in the implementation of effective control measures. However, isolation of the agent(s) from crude clinical samples can be challenging and time-consuming, hindering the establishment of countermeasures. In the present study, we used saliva specimens collected for the diagnosis of SARS-CoV-2—a good example of a practical target—and attempted to characterize the virus within the specimens without virus isolation. Thirty-four saliva samples from coronavirus disease 2019 patients were used to extract RNA and synthesize DNA amplicons by PCR. New primer sets were designed to generate DNA amplicons of the full-length spike (S) gene for subsequent use in a circular polymerase extension reaction (CPER), a simple method for deriving recombinant viral genomes. According to the S sequence, four clinical specimens were classified as BA. 1, BA.2, BA.5, and XBB.1 and were used for the de novo generation of recombinant viruses carrying the entire S gene. Additionally, chimeric viruses carrying the gene encoding GFP were generated to evaluate viral propagation using a plate reader. We successfully used the RNA purified directly from clinical saliva samples to generate chimeric viruses carrying the entire S gene by our updated CPER method. The chimeric viruses exhibited robust replication in cell cultures with similar properties. Using the recombinant GFP viruses, we also successfully characterized the efficacy of the licensed antiviral AZD7442. Our proof-of-concept demonstrates the novel utility of CPER to allow rapid characterization of viruses from clinical specimens. IMPORTANCE Characterization of the causative agent(s) for infectious diseases helps in implementing effective control measurements, especially in outbreaks. However, the isolation of the agent(s) from clinical specimens is often challenging and time-consuming. In this study, saliva samples from coronavirus disease 2019 patients were directly subjected to purifying viral RNA, synthesizing DNA amplicons for sequencing, and generating recombinant viruses. Utilizing an updated circular polymerase extension reaction method, we successfully generated chimeric SARS-CoV-2 viruses with sufficient in vitro replication capacity and antigenicity. Thus, the recombinant viruses generated in this study were applicable for evaluating the antivirals. Collectively, our developed method facilitates rapid characterization of specimens circulating in hosts, aiding in the establishment of control measurements. Additionally, this approach offers an advanced strategy for controlling other (re-)emerging viral infectious diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2COVID-19SalivaRNA, ViralHumansSpike Glycoprotein, CoronavirusGenome, ViralAnimals

Stichwörter der Autor:innen

SARS-CoV-2clinical specimensreporter assayreverse genetics

Substanzen

RNA, ViralSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Autor:innen und Institutionen

  • Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
  • Institute for Vaccine Research and Development (IVReD), Hokkaido University, Sapporo, Japan.
  • One Health Research Center, Hokkaido University, Sapporo, Japan.
  • Department of Hematology, Faculty of Medicine, Hokkaido University, Sapporo, Japan.
  • Department of Hematology, Sapporo City General Hospital, Sapporo, Japan.
  • Department of Clinical Laboratory Testing, Sapporo City General Hospital, Sapporo, Japan.

ORCID-Profile: Hirotaka Yamamoto, Tomokazu Tamura, Takanori Teshima, Takasuke Fukuhara

Förderung

  • Japan Agency for Medical Research and Development (AMED)
  • MEXT | Japan Society for the Promotion of Science (JSPS)
  • MEXT | Japan Science and Technology Agency (JST)
  • Hirose Foundation (ヒロセ)
  • Hokuto Foundation for Bioscience
  • Takeda Science Foundation (TSF)
  • Hokkaido University (HU)

Zitieren

APA

Yamamoto, H., Tamura, T., Ichikawa, T., Taguchi, Y., Mori, K., Oguri, S., Suzuki, R., Suzuki, S., Teshima, T., & Fukuhara, T. (2024). Generation of recombinant viruses directly from clinical specimens of COVID-19 patients. Journal of Clinical Microbiology. https://doi.org/10.1128/jcm.00042-24

Vancouver

Yamamoto H, Tamura T, Ichikawa T, Taguchi Y, Mori K, Oguri S, et al. Generation of recombinant viruses directly from clinical specimens of COVID-19 patients. Journal of Clinical Microbiology. 2024. doi:10.1128/jcm.00042-24

BibTeX
@article{Yamamoto2024,
  author = {Yamamoto, Hirotaka and Tamura, Tomokazu and Ichikawa, Takaya and Taguchi, Yudai and Mori, Kento and Oguri, Satoshi and Suzuki, Rigel and Suzuki, Saori and Teshima, Takanori and Fukuhara, Takasuke},
  title = {Generation of recombinant viruses directly from clinical specimens of COVID-19 patients},
  journal = {Journal of Clinical Microbiology},
  year = {2024},
  doi = {10.1128/jcm.00042-24}
}
Kostenlos starten →